Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 33,170 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
Interventions: Naloxone, Diazoxide, Placebo (for Naloxone), Placebo (for Diazoxide); Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years to 55 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Cardiac Allograft Vasculopathy
Interventions: ramipril, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 12 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: Post-Traumatic Stress Disorder
Interventions: orvepitant, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 26
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 23 more

Conditions: Immune
Interventions: Amunizer, Placebo; Dietary Supplement · Other
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 20 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Reproductive Issues
Interventions: Vitamin D, Placebo; Dietary Supplement · Other
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 19 Years to 40 Years · Female only
Enrollment: 998 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Detroit, Michigan • Research Triangle Park, North Carolina

Conditions: Axial Myopia, Refractive Errors
Interventions: Oral Riboflavin; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 6 Years to 12 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Engensis, Placebo; Biological · Other
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
Interventions: Exparel (Bupivacaine Liposome), Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy Volunteers
Interventions: LY2484595, Placebo, Moxifloxacin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 2
States / cities: Daytona Beach, Florida • Evansville, Indiana

Conditions: Healthy
Interventions: VIS954, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy
Interventions: 0.1 mg PF-04995274, 1 mg PF-04995274, 10 mg PF-04995274, 15 mg PF-04995274, 1.0 mg PF-04995274; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: VAY736, Placebo, Standard of Care (SoC); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 7
States / cities: Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 4 more

Conditions: Inflammation
Interventions: Omega 7 + 3, Omega 3, Placebo; Dietary Supplement
Lead sponsor: Appalachian State University; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Type 2 Diabetes, Chronic Kidney Disease
Interventions: Zemplar, Placebo; Drug
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 4
States / cities: Atlanta, Georgia • New Orleans, Louisiana • Boston, Massachusetts + 1 more

Conditions: Clostridium Difficile, Clostridium Infections
Interventions: SYN-004, Placebo; Drug
Lead sponsor: Theriva Biologics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Little Rock, Arkansas • Torrance, California • DeLand, Florida + 3 more

Conditions: Gastric Motility Disorder
Interventions: Methylnaltrexone only, Codeine only, Methylnaltrexone + codeine, Placebo + placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Clostridium Difficile Colitis
Interventions: CRS3123, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diarrhea, Gastroenteritis
Interventions: Zinc Sulfate, Placebo oral capsule; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Months to 6 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: PTSD
Interventions: Quetiapine, Placebo; Drug
Lead sponsor: Ralph H. Johnson VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 2
States / cities: Albuquerque, New Mexico • Charleston, South Carolina

Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Interventions: Anakinra, Placebo; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Day to 17 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 32
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 28 more

Conditions: Type 2 Diabetes
Interventions: Placebo, Exenatide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more

Conditions: Crohn´s Disease
Interventions: Pentasa, Placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: San Diego, California • Clearwater, Florida • John's Creek, Georgia + 4 more

Conditions: Obesity
Interventions: pramlintide acetate, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 21
States / cities: Chula Vista, California • San Diego, California • Walnut Creek, California + 18 more

Conditions: Prader-Willi Syndrome
Interventions: Octreotide, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 5 Years to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy

Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder

Beverage for Immune Support

The Investigation of Vitamin D and Menstrual Cycles Trial, the inVitD Trial: A Phase II Clinical Trial

Evaluation of Progression of Myopia in Children Treated With Vitamin B2 and Outdoor Sunlight Exposure

A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

A Study of LY2484595 on the Electrical Activity of the Heart

A Study to Evaluate Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Multiple Doses of VIS954

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

Omega 7 + 3 Combination and Systemic Inflammation

Effect Of Paricalcitol (Zemplar) On Endothelial Function And Inflammation In Type 2 Diabetes And Chronic Kidney Disease

A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI

Effect of Methylnaltrexone on GI Transit in Healthy Volunteers

Phase I Trial of a Single Dose of CRS3123

Oral Zinc for the Treatment of Acute Diarrhea in US Children

Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

A Study With Pentasa in Patients With Active Crohn's Disease

A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)